健友股份(603707.SH)：子公司获得美国FDA注射用维库溴铵药品增加生产场地注册批件

Core Viewpoint - The company, Jianyou Co., Ltd. (健友股份), announced that its subsidiary, Meitheal Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration (FDA) to increase production capacity for injectable vecuronium bromide, with dosages of 10 mg/vial and 20 mg/vial [1] Group 1 - The FDA approval pertains to the production of vecuronium bromide, which is used as an adjunct to general anesthesia to facilitate tracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation [1] - The production will take place at the Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. facility [1]